Sort
39,280 grants matching “leukemia”
Novel Strategies for Treatment of Myeloproliferative Disorders
$352,750Roya Khosravi-Far · Beth Israel Deaconess Medical Center · R01 · FY2008 · CA
Novel Strategies for Treatment of Myeloproliferative Disorders
$352,750Roya Khosravi-Far · Beth Israel Deaconess Medical Center · R01 · FY2010 · CA
Cellular Immunity Targeting Epithelial Ovarian Cancer
$352,723Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2008 · CA
Development of gene therapy for wiskott-aldrich syndrome (WAS)
$352,716Arthur W. Nienhuis · St. Jude Children'S Research Hospital · P01 · FY2010 · HL
Evaluation of self-inactivating lentiviral vectors for treating SCID-X1 patients
$352,716Brian P Sorrentino · St. Jude Children'S Research Hospital · P01 · FY2010 · HL
Microenvironmental Regulation of Leukemia Stem Cells
$352,688Ravi Bhatia · University Of Alabama At Birmingham · R01 · FY2020 · CA
Microenvironmental Regulation of Leukemia Stem Cells
$352,688Ravi Bhatia · University Of Alabama At Birmingham · R01 · FY2019 · CA
Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia
$352,688Michael W Deininger · Versiti Wisconsin, Inc. · R01 · FY2024 · CA
Microenvironmental Regulation of Leukemia Stem Cells
$352,688Ravi Bhatia · University Of Alabama At Birmingham · R01 · FY2021 · CA
Control of retrovirus CNS disease by redox modulation
$352,687University Of Texas Md Anderson Can Ctr · R01 · FY2003 · NS
Microfluidic Techniques for the Molecular and Functional Analysis of Gene Express
$352,626Stephen R Quake · Stanford University · P01 · FY2013 · CA
HTS enabled examination of drug combinations
$352,622Craig Thomas · National Center For Advancing Translational Sciences · ZIA · FY2021 · TR
Diagnosis of Cancer in the Emergency Room - Explaining Persistent Disparities
$352,620Caroline Avery Thompson · Univ Of North Carolina Chapel Hill · R01 · FY2021 · CA
Targeted Radiotherapy with 90Y-BC8 Monclonal Antibody, Fludarabine and TBI Follow
$352,615William I Bensinger · Fred Hutchinson Cancer Research Center · R21 · FY2011 · CA
Post-translational regulation of Lis1/Pac1p in dynein function
$352,601Rita K Miller · Oklahoma State University Stillwater · R15 · FY2016 · GM
A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients
$352,587Manuel B Datiles · National Eye Institute · ZIA · FY2015 · EY
APPLYING ERROR-CORRECTED SEQUENCING TO DETECT MINIMAL RESIDUAL IN THE AAML 1031 STUDY
$352,587Todd E Druley · Washington University · R01 · FY2020 · CA
APPLYING ERROR-CORRECTED SEQUENCING TO DETECT MINIMAL RESIDUAL IN THE AAML 1031 STUDY
$352,587Todd E Druley · Washington University · R01 · FY2021 · CA
APPLYING ERROR-CORRECTED SEQUENCING TO DETECT MINIMAL RESIDUAL IN THE AAML 1031 STUDY
$352,587Todd E Druley · Washington University · R01 · FY2018 · CA
MECHANISMS BY WHICH IFN-GAMMA SEPARATES GVHD AND GVL
$352,577Yong-Guang Yang · Massachusetts General Hospital · P01 · FY2009 · CA
The Osteoblast as a Determinant of Leukemogenesis
$352,518Stavroula Kousteni · Columbia University Health Sciences · R01 · FY2013 · AR
HUMAN PLATELET IN IMMUNOHEMATOLOGIC DISEASE
$352,517University Of Pennsylvania · R01 · FY2001 · HL
Myeloid cell-derived Granzyme B as an inducible enhancer of cancer immunotherapy
$352,513Susheela Tridandapani · Ohio State University · R01 · FY2021 · CA
Targeting Serine Auxotrophy in Luminal Breast Cancer
$352,495Jonathan L. Coloff · University Of Illinois At Chicago · R37 · FY2023 · CA
The role of reorganization energy in achieving selective kinase inhibition
$352,465John Damon Chodera · Sloan-Kettering Inst Can Research · R01 · FY2020 · GM